UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapies for dopaminergic-induced dyskinesias in parkinson disease

Annals of neurology, 2011-06, Vol.69 (6), p.919-927

2011

Volltextzugriff (PDF)

A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus

The New England journal of medicine, 2001-08, Vol.345 (9), p.631-637

2001

Volltextzugriff (PDF)

Multiple Dorsal Hand Actinic Keratoses and Squamous Cell Carcinomas: A Unique Presentation following Extensive UV Nail Lamp Use

Case reports in dermatology, 2019-09, Vol.11 (3), p.286-291

2019

Volltextzugriff (PDF)

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

The New England journal of medicine, 2023-09, Vol.389 (11), p.998-1008

2023

Volltextzugriff (PDF)

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

Gut, 2024-08, Vol.73 (8), p.1343-1349

2024

Volltextzugriff (PDF)

Resistive detection of nuclear spins in a single quantum dot under Kondo effect regime

Physical review. B, Condensed matter and materials physics, 2013-02, Vol.87 (8), Article 081303

2013

Volltextzugriff (PDF)

Phase behavior of ionic microgels

Physical review letters, 2004-02, Vol.92 (6), p.068301-068301, Article 068301

2004

Volltextzugriff (PDF)

Atypical Mycobacterial Infection Arising Amid Corticosteroid Therapy for Livedoid Vasculopathy

Case reports in dermatological medicine, 2019, Vol.2019 (2019), p.1-5

2019

Volltextzugriff (PDF)

Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics

The Journal of chemical physics, 2005-02, Vol.122 (7), p.074903-074903

2005

Volltextzugriff (PDF)

Repigmentation of Tenacious Vitiligo on Apremilast

Case reports in dermatological medicine, 2017-01, Vol.2017 (2017), p.1-3

2017

Volltextzugriff (PDF)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial

Movement disorders, 2021-10, Vol.36 (10), p.2408-2412

2021

Volltextzugriff (PDF)

507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1037-S1038

2016

Volltextzugriff (PDF)

Formation of polymorphic cluster phases for a class of models of purely repulsive soft spheres

Physical review letters, 2006-02, Vol.96 (4), p.045701-045701, Article 045701

2006

Volltextzugriff (PDF)

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status

Expert opinion on investigational drugs, 1999-10, Vol.8 (10), p.1673-1682

1999

Volltextzugriff (PDF)

New pharmacotherapy for Parkinson's disease

The Annals of pharmacotherapy, 1997-10, Vol.31 (10), p.1205-1217

1997

Volltextzugriff (PDF)

Pharmacokinetics of Fosphenytoin in Patients with Hepatic or Renal Disease

Epilepsia (Copenhagen), 1999-06, Vol.40 (6), p.777-782

1999

Volltextzugriff (PDF)

Predicting equilibrium structures in freezing processes

The Journal of chemical physics, 2005-05, Vol.122 (20), p.204503-204503

2005

Volltextzugriff (PDF)

Natriuretic and Neurohormonal Responses to Nesiritide, Furosemide, and Combined Nesiritide and Furosemide in Patients With Stable Systolic Dysfunction

Clinical cardiology (Mahwah, N.J.), 2010-06, Vol.33 (6), p.330-336

2010

Volltextzugriff (PDF)

Prehospital stability of diazepam and lorazepam

The American journal of emergency medicine, 1999-07, Vol.17 (4), p.333-337

1999

Volltextzugriff (PDF)

WED-235 Prediction of metabolic dysfunction-associated steatohepatitis resolution

Journal of hepatology, 2024-06, Vol.80, p.S522-S523

2024

Volltextzugriff (PDF)

Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis

Metabolism, clinical and experimental, 2024-06, Vol.153, p.155873, Article 155873

2024

Volltextzugriff (PDF)

Pegozafermin Added to Background GLP-1 Therapy Led to Greater Improvement in Non-invasive Markers of Liver Fat, Injury and Fibrosis as well as Glycemic Control in NASH Patients with F2/F3 Fibrosis at 24 weeks: A Posthoc Analysis from ENLIVEN

Metabolism, clinical and experimental, 2024-06, Vol.153, p.155874, Article 155874

2024

Volltextzugriff (PDF)

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: review and current status

Expert opinion on investigational drugs, 1999-04, Vol.8 (4), p.453-462

Gottwald, Mildred D

1999

Volltextzugriff (PDF)

Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes

American journal of health-system pharmacy, 2000-05, Vol.57 (10), p.953-962

2000

Volltextzugriff (PDF)

SAT-203 Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data

Journal of hepatology, 2024-06, Vol.80, p.S607-S608

2024

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(250)
Mit Volltextzugriff
(295)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(164)
Physical Sciences
(73)
Life Sciences & Biomedicine
(71)
Physics
(60)
Humans
(45)
Technology
(44)
Biological And Medical Sciences
(35)
Female
(23)
Engineering
(21)
Male
(21)
Physics, Applied
(20)
Adult
(18)
Engineering, Electrical & Electronic
(18)
Exact Sciences And Technology
(18)
Medical Sciences
(18)
Plant Sciences
(18)
Chemistry
(17)
Fundamental And Applied Biological Sciences. Psychology
(17)
Materials Science
(15)
Physics, Atomic, Molecular & Chemical
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Therapies for dopaminergic-induced dyskinesias in parkinson disease

A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus

Multiple Dorsal Hand Actinic Keratoses and Squamous Cell Carcinomas: A Unique Presentation following Extensive UV Nail Lamp Use

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

Resistive detection of nuclear spins in a single quantum dot under Kondo effect regime

Phase behavior of ionic microgels

Atypical Mycobacterial Infection Arising Amid Corticosteroid Therapy for Livedoid Vasculopathy

Ionic microgels as model systems for colloids with an ultrasoft electrosteric repulsion: structure and thermodynamics

Repigmentation of Tenacious Vitiligo on Apremilast

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial

507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data

Formation of polymorphic cluster phases for a class of models of purely repulsive soft spheres

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status

New pharmacotherapy for Parkinson's disease

Pharmacokinetics of Fosphenytoin in Patients with Hepatic or Renal Disease

Predicting equilibrium structures in freezing processes

Natriuretic and Neurohormonal Responses to Nesiritide, Furosemide, and Combined Nesiritide and Furosemide in Patients With Stable Systolic Dysfunction

Prehospital stability of diazepam and lorazepam

WED-235 Prediction of metabolic dysfunction-associated steatohepatitis resolution

Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis

Pegozafermin Added to Background GLP-1 Therapy Led to Greater Improvement in Non-invasive Markers of Liver Fat, Injury and Fibrosis as well as Glycemic Control in NASH Patients with F2/F3 Fibrosis at 24 weeks: A Posthoc Analysis from ENLIVEN

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: review and current status

Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes

SAT-203 Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data

Suchergebnisse filtern